media – Page 36 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Fatty Foods Might Contribute To Childhood Asthma

By Dennis Thompson HealthDay ReporterTHURSDAY, Aug. 28, 2025 (HealthDay News) — Fatty foods might contribute to asthma in children, a new study says. Fats found in certain foods are linked to neutrophilic asthma, a non-allergic type of asthma triggered by microbial and bacterial proteins, researchers reported Aug. 27 in the journal Science Translational Medicine. Specifically, a type of saturated fatty acid called stearic acid – often found in animal fat and processed foods – appears to start a chain reaction that can lead to neutrophilic asthma, researchers said. “Prior to this study, many suspected that childhood obesity was causing this form of asthma,” said senior researcher Dr. David Hill, an attending physician in allergy and immunology at Children’s Hospital of Philadelphia. “However, we were observing neutrophilic asthma in children who weren’t obese, which is why we suspected there might be another mechanism,” Hill said in a news release. “What we ...
- Source: drugdu
- 120
- August 29, 2025
Clinical research of SGC001, a drug in which Regeneron Biopharma holds a stake, is progressing smoothly.

On August 28, Rejing Bio(688068) issued an announcement that it recently received a request from a joint venture company for an innovative drugA progress report on the Phase I clinical study of SGC001 injection. The project has completed a Phase Ia clinical study in healthy volunteers, and the Phase Ib clinical study in patients with anterior ST-segment elevation myocardial infarction is progressing smoothly. Clinical observations of all subjects have been completed, and the clinical study was unblinded on August 27. SGC001 injection, developed jointly by Sungene’s R&D team and other institutions, is indicated for the emergency treatment of patients with acute myocardial infarction. The drug’s clinical trial application has been approved by the FDA and CDE, and it received FDA Fast Track designation in March 2025. Currently, complete efficacy and safety information from the Phase Ib trial will be disclosed in the official data analysis report, and will not have ...
- Source: drugdu
- 70
- August 29, 2025
Walvax Biopharma’s 23-valent pneumococcal vaccine enters the Latin American market for the first time

Recently, Yunnan Walvax BioThe 23-valent pneumococcal polysaccharide vaccine ( hereinafter referred to as ” 23-valent pneumococcal vaccine”) produced by Yuxi Walvax Biotechnology Co. , Ltd., a subsidiary of Walvax Biotechnology Co., Ltd. (hereinafter referred to as “Walvax Biotechnology”), has completed its first export delivery to El Salvador. This milestone event marks the first export of Walvax Biotechnology to El Salvador.The product officially entered the Latin American market, further expanding its global layout. According to data disclosed by Walvax Bio, as the world’s first preservative-free 23-valent pneumococcal polysaccharide vaccine, this product is suitable for children over 2 years old and high-risk adults. The cumulative global sales volume has exceeded 14 million doses. As of now, Walvax Bio has built a diversified global vaccine supply network. Its products, including 13-valent pneumococcal polysaccharide conjugate vaccine, bivalent human papillomavirus vaccine (Pichia pastoris), 23-valent pneumococcal vaccine, ACYW135 group meningococcal polysaccharide vaccine, group A and group C meningococcal ...
- Source: drugdu
- 114
- August 29, 2025
Yabao Pharmaceutical’s subsidiary, SY-005 Injection, has been approved for clinical trials in the treatment of gliomas.

On August 25, Yabao Pharmaceutical(600351) issued an announcement that its controlling subsidiary Suzhou Yabao Pharmaceutical Research and Development Co., Ltd. recently received the “Drug Clinical Trial Approval Notice” for the new indication of SY-005 injection approved and issued by the National Medical Products Administration. The approval notice allows the clinical trial of SY-005 injection for the treatment of neurological deficits after glioma surgery. The application is for the treatment of neurological deficits after glioma surgery, and the drug registration classification is a therapeutic biological product.Category 1. As of the date of this announcement, the company has invested approximately RMB 127 million in R&D for the SY-005 project. SY-005 is an innovative recombinant protein .In November 2018, the company received approval for a clinical trial for the treatment of sepsis, and this indication is currently in Phase II clinical trials. Glioma is the most common primary intracranial malignant tumor, and postoperative ...
- Source: drugdu
- 77
- August 29, 2025
Genfleet Pharmaceutical passed the Hong Kong Stock Exchange hearing

The Hong Kong Stock Exchange’s official website indicates that Jinfang Pharmaceuticals (Shanghai) Co., Ltd. has passed its hearing and is poised to list on the Hong Kong Stock Exchange. The prospectus states that Jinfang Pharmaceuticals, founded in 2017, is a biopharmaceutical company focused on developing novel treatment options for oncology (covering various lines of treatment for various solid tumors) as well as autoimmune and inflammatory diseases. Currently, Jinfang Pharmaceuticals has established a product pipeline consisting of eight drug candidates, five of which are in clinical development. Comment: Jinfang Pharmaceuticals, which has passed its Hong Kong Stock Exchange hearing, focuses on oncology and immune diseases. Its pipeline includes eight drug candidates, five of which are in clinical trials. A successful IPO could accelerate R&D, but the company faces intense competition in the field. https://finance.eastmoney.com/a/202508273495486977.html
- Source: drugdu
- 74
- August 29, 2025
Xinhua Bio completed tens of millions of US dollars in Series A financing

On August 25th, Xinhua Bio announced the completion of a multi-million dollar Series A financing round. The Series A+ round was led by Xingze Capital, while the Series A round was led by Sany Innovation Investment, with participation from other existing shareholders, including Sequoia China. The funds will be primarily used to advance the company’s core pipeline into global clinical trials, accelerate research and development, and provide more effective treatment options for patients worldwide. Comment: Xinhua Biopharma received tens of millions of US dollars in Series A financing. The funds will help its core pipeline enter global clinical trials, accelerate research and development, and highlight its research and development potential and market value in fields such as tumor immunology. https://finance.eastmoney.com/a/202508273495486977.html
- Source: drugdu
- 68
- August 29, 2025
Inxmed plans to go public in Hong Kong

According to the Hong Kong Stock Exchange’s official website, InxBio has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Securities and CCB International acting as joint sponsors. Founded in 2017, InxBio is a late-stage clinical-stage biotech company dedicated to improving current oncology treatments, which have limited efficacy. Its mission is to address the core challenge of cancer treatment: drug resistance caused by tumor defenses. Comment: Inspiron Biopharma plans to list in Hong Kong, focusing on addressing drug resistance in tumors. Its core products have potential. However, the company’s products are not commercialized, and it continues to lose money. Its capital needs are substantial, and its listing and profitability are uncertain. https://finance.eastmoney.com/a/202508273495486977.html
- Source: drugdu
- 78
- August 29, 2025
ReiPhase 3 clinical study of oral GLP-1RA orforglipron in obesity and type 2 diabetes was successful

Eli Lilly recently announced positive topline results from the Phase 3 ATTAIN-2 clinical trial of its investigational GLP-1 receptor agonist orforglipron. The study targeted obese or overweight adults with type 2 diabetes. In the ATTAIN-2 study, all three dose groups of orforglipron met the primary endpoint and all key secondary endpoints, achieving significant weight loss, clinically meaningful reductions in glycated hemoglobin (A1C), and improvements in cardiovascular risk factors at 72 weeks. Comment: Eli Lilly ‘s successful Phase 3 ATTAIN-2 clinical trial of orforglipron offers hope for patients with obesity and type 2 diabetes. The drug demonstrated significant weight loss and A1C reduction, while also improving cardiovascular risk factors. Oral administration is more convenient than injectable GLP-1RAs. If approved for marketing, it has the potential to reshape the treatment landscape, transform patient lifestyles, and usher in new market trends. https://finance.eastmoney.com/a/202508273495486977.html
- Source: drugdu
- 73
- August 29, 2025
Bayer’s small molecule PRMT5 inhibitor has been approved for clinical trials in China

The official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (CFDA) announced that Bayer has received implicit approval for clinical trials for its Category 1 new drug, BAY 3713372 tablets, intended for the treatment of methylthioadenosine phosphorylase-deficient (MTAP-DEL) solid tumors. This is an oral small molecule PRMT5 inhibitor. In March of this year, Bayer and Puhe Pharmaceuticals announced a global licensing agreement, granting them exclusive global rights to develop, manufacture, and commercialize this product. Comment: Bayer’s small molecule PRMT5 inhibitor has received clinical approval in China, which is expected to bring new hope to patients with MTAP-DEL solid tumors.It selectively targets cancer cells, has high safety, and has received technical support through cooperation with Puhe Pharmaceutical. Subsequent clinical data is highly anticipated. https://finance.eastmoney.com/a/202508273495486977.html
- Source: drugdu
- 82
- August 29, 2025
【EXPERT Q&A】What are the development trends of the complex formulation industry?

Drugdu.com expert’s response: Development Trends in the Complex Formulation Industry I. Complex formulation processes will gain broader development opportunities Formulation innovation can extend the lifecycle of new molecular entities while enhancing the safety, efficacy, and patient compliance of existing products, making it a focal point of pharmaceutical R&D. For instance, conventional leuprolide formulations have gradually been phased out, whereas leuprolide microspheres remain a first-line treatment for prostate cancer and uterine fibroids. In 2022, the market size of leuprolide microspheres in China reached approximately RMB 4.8 billion, with steady year-on-year growth. China’s 14th Five-Year Plan for the Pharmaceutical Industry emphasizes the need to prioritize the development of complex formulation technologies for chemical drugs, including high-selectivity, long-acting controlled-release injectables (e.g., microspheres) and oral formulations such as controlled-release and multi-particulate systems. Enterprises mastering innovative complex formulation processes are poised to stand out and secure greater profit margins. II. Significant potential for import substitution by domestic ...
- Source: drugdu
- 195
- August 29, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.